

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bamford <i>et al.</i>	Confirmation No.: 4857
Serial No.: 10/539,385	Group Art Unit: 1624
Filed: June 16, 2005	Examiner: B. Coleman
Title: BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

The section of the application entitled "Results" [page 96 of Publication No. WO 2004/056369 (PCT/EP2003/014556)] states that the compound of Example 121 exhibits antagonism $>9.5\text{pK}_b$. It is noted for the record that the hydrochloride salt of the compound of Example 121 exhibits antagonism $>9.5\text{pK}_b$. The free base of the compound of Example 121 exhibits antagonism of approximately 9.2pK_b .

It is submitted that the above information is not material to patentability. Nevertheless, this information is presented to correct the record. If the Examiner has any questions concerning this information, please contact the undersigned.

Respectfully submitted,

Date: 31 July 2007


Bonnie L. Deppenbrock
Attorney of Record
Registration No. 28,209

Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988

ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON July 31, 2007.